Background and Design: How oral lichen planus (OLP) affects oral health-related quality of life has been shown in previous studies but only symptomatic erosive and ulcerative OLP patients were included in such studies. The aim of this study was to determine if oral health-related quality of life is affected in patients with OLP, not only erosive but also reticular form of OLP. Materials and Methods: Patients who were diagnosed with OLP in the dermatology outpatient clinic and age-and gender-matched healthy individuals were included in this study. Oral health-related quality of life was assessed by using the 14-item OHIP (Oral Health Impact Profile)-14 in all participants. Results: Forty patients with OLP and 40 healthy subjects were included in this study. Mixed type lesions were present in 25% of patients while solely reticular lesions were present in 75%. OLP was painful and oral functions were affected in 50% of patients. There was a statistically significant difference in median OHIP-total score between patient and control groups. The median OHIP-14 total score in lichen planus patients and controls was 8.5 and 3. However, there was no significant difference between patients with solely reticular lesions and those with mixed type lesions. Conclusion: In this study, we have shown that oral health-related quality of life was affected both in patients with only reticular lesions and in patients with mixed type lesions.

No abstract

Psoriasis is a complex, chronic, and immune-mediated inflammatory disease affecting almost 2.5% of the world population. 1 Psoriasis is primarily a dermatological condition that is most often associated with other comorbidities, including psoriatic arthritis, hypertension, diabetes mellitus, obesity, psychiatric disorders, and systemic inflammation beyond the skin. Effective, safe, and long-term management of psoriasis is important in controlling skin lesions and preventing metabolic and psychiatric comorbidities. 2 New treatment

Background Dupilumab is approved for the treatment of atopic dermatitis (AD). However, there are few studies demonstrating its efficacy and safety, particularly in the treatment of adult‐onset AD. Objective The aim of this study is to evaluate the real‐life experience regarding the efficacy and safety of dupilumab in the treatment of adult‐onset AD. Methods This study is a case series in retrospective design. Patients with the diagnosis of adult‐onset AD, using dupilumab at a standard dose for at least 3 months, were included in the study. Demographic and laboratory data of the cases, data regarding to dupilumab treatment, were recorded. The eczema area severity index (EASI) and the visual analog scale (VAS) for itch were used to evaluate treatment efficacy. Results A total of 16 patients, 6 female and 10 male, were included. The median age was 41 years, the median age of the disease onset was 37.5 years, and the median duration of the disease was 90 months. The median duration of the dupilumab treatment was 10.5 months. The mean percent reduction from baseline in EASI score was 85.8 ± 12.2 at 3 months, 90.7 ± 9.3 at 6 months, and 93.1 ± 5 at 12 months. The mean percent reduction from baseline in VAS itch score was 82.2 ± 8.6 at 3 months. Acute vestibular neuritis was developed in one patient during the dupilumab therapy and resolved with anti‐inflammatory therapy. Conclusion Dupilumab seems to be highly effective and safe in the treatment of adult‐onset AD. The present study is important as it is the first study to evaluate this patient group specifically.

El-ayak-ağız hastalığı (EAAH), genellikle çocuklarda görülen akut enfeksiyöz bir hastalık olup; tipik olarak el, ayak ve oral kavitede makülopapüler veya veziküler erüpsiyonlarla karakterizedir. Bölgemizde, geçtiğimiz kış ve sonbahar aylarında, kliniğimize başvuran erişkin EAAH tanılı hasta sayısında artış tespit ettik. EAAH'dan etkilenen erişkin populasyonun artan insidansı nedeni ile bu populasyonda hastalık seyrinin ve morfolojik özelliklerinin belirlenmesi amaçlanmıştır. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : Çalışmamıza, Ekim 2014-Kasım 2015 tarihleri arasında polikliniğimize başvuran 27 hasta dâhil edildi. Demografik veriler, prodromal belirtiler, şikâyetler, fizik muayene bulguları, benzer belirtileri olan kişilerle temas öyküsü, tedavi yaklaşımları, iyileşme süresi ve sistemik komplikasyonları değerlendirildi. EAAH tanısı hastalık öyküsü ve cilt lezyonlarının tipik görünüm ve dağılımına dayanılarak konuldu. Hastalar semptomatik olarak tedavi edildi. B Bu ul lg gu ul la ar r: : Çalışmaya katılan 27 (19 erkek, sekiz kadın) hastanın ortalama yaşları 28±8,14 yıl idi. En sık görülen prodromal semptom hâlsizlik idi. Makülopapüler deri döküntüsü en sık görülen klinik bulguydu. Krut izlenen hastalarda iyileşme zamanı daha uzun ve istatistiksel olarak anlamlıydı. Ülser izlenen hastalarda ortalama yaş anlamlı derecede yüksek saptandı. Hastaların %44 (n:12)'ünde benzer döküntüsü olan çocuklarla temas öyküsü mevcuttu. S So on nu uç ç: : El-ayak-ağız hastalığı için ayırıcı tanıda eritema multiforme, ikinci evre sifiliz, ilaç erüpsiyonu, diğer viral enfeksiyonlar, enfektif tromboemboli ve vaskülit akla gelmelidir. Ülser sıklığının yaş ile orantılı olarak artması hastalığın yaş ilerledikçe deri bulguları açısından daha şiddetli seyredebileceği görüşünü akla getirmektedir. Son yıllara erişkin EAAH sıklığı giderek artmaktadır. Bu bağlamda bu çalışmada, el ve ayakta döküntüleri ile başvuran erişkin hastalarda EAAH'nin ayırıcı tanıda akılda tutulmasının sağlanması ve klinik özelliklerinin hatırlatılması amaçlanmıştır.